Medications for Opioid Use Disorder
1)
According to SAMHSA and NIDA, opioid addiction is best understood as:
2)
What has been shown to improve retention and outcomes for people with OUD?
3)
Methadone treatment is supported by:
4)
How should providers decide when to discontinue OUD medication?
5)
Why is medically supervised withdrawal required before starting naltrexone?
6)
What major policy change did SAMHSA implement in 2024 regarding opioid treatment programs (OTPs)?
7)
If a provider does not offer medication for OUD, what is the priority?
8)
Why is assessing for comorbid mental illness important in patients with OUD?
9)
Why is gathering social history important in OUD treatment planning?
10)
What does the severity of opioid withdrawal help determine?
11)
A negative opioid test without withdrawal symptoms most likely indicates:
12)
When may family members be included in treatment planning?
13)
At the start of methadone treatment in an OTP, how often must patients typically visit?
14)
Which patients may be appropriate candidates for residential treatment?
15)
What types of services may support patients receiving OUD medication?
16)
What should providers understand about relapse during recovery?
17)
What have short-term pilot studies shown about offering XR-NTX before release from controlled environments?
18)
Which option can relieve some withdrawal symptoms when opioid agonist medications are unavailable?
19)
Which methadone formulation is most commonly used in treatment programs?
20)
When do patients typically feel the full effect of their methadone dose?
21)
What safety advice should be given to patients beginning methadone treatment?
22)
Which reproductive-related side effect may occur with methadone use?
23)
During the first 90 days of OTP treatment, how many take-home doses are typically allowed per week?
24)
What is the generally recommended safety limit for the first day’s methadone dosing?
25)
Which factor would OTP medical directors consider before approving take-home doses?
26)
Who should be tested annually for hepatitis C?
27)
Which group is not an appropriate candidate for XR-NTX treatment?
28)
Why might some patients stop using illicit opioids after starting XR-NTX?
29)
Why should unstable patients be discouraged from stopping treatment?
30)
When should patients take their first buprenorphine dose during home induction?
31)
What is the primary goal of buprenorphine treatment?
32)
How should treatment success be measured?
33)
Why is adequate pain management important in patients with OUD?
34)
Can pregnant women on buprenorphine continue the medication during labor?
35)
How does the American Society of Addiction Medicine define addiction?
36)
Which of the following is a key feature of OUD per DSM-5?
37)
Why are longer courses of OUD medication beneficial?
38)
Which of the following is an example of building recovery capital?
39)
What is a key feature of trauma-informed care?
40)
What happens in the brain when opioids activate receptors and the nucleus accumbens (NAc)?
41)
Why do environmental cues become triggers for drug use?
42)
Who is especially at risk of methadone overdose?
43)
When do patients typically begin buprenorphine treatment?
44)
What can prescribers do if XR-NTX effectiveness declines before the next dose?
45)
What strategy can encourage patients to return to treatment after relapse?